Efficacy and safety of metformin-sitagliptin combination for the treatment of patients with diabetes mellitus and obesity
https://doi.org/10.14341/2072-0351-5490
Abstract
Aim.
To elucidate therapeutic effect of metformin-sitaglitin combination on the dynamics of indices of insulin resistance and functional activity of pancreaticbeta-cells, lipid metabolism and body weight in patients with type 2 diabetes mellitus (DM2) and obesity.
Materials and methods.
The study included 32 patients treated by a combination of metformin (500-2550 mg/day) and sitagliptin (100 mg) for18 weeks. Standard parameters of carbohydrate and lipid metabolism, body mass index (BMI), blood adiponectin and leptin levels were measured, indices of insulin resistance and functional activity of pancreatic beta-cells were calculated.
Results.
Therapy with metformin-sitagliptin combination ensured compensation of fasting and postprandial hyperglycemia, reduced HbA1c level, increasedfunctional activity of beta-cells, decreased peripheral insulin resistance and BMI, had beneficial effect on lipid metabolism and hormonalactivity of adipose tissue.
Conclusion.
Metformin-sitagliptin combination can be recommended as a clinically efficacious modality for the treatment of patients with diabetesmellitus and obesity.
To elucidate therapeutic effect of metformin-sitaglitin combination on the dynamics of indices of insulin resistance and functional activity of pancreaticbeta-cells, lipid metabolism and body weight in patients with type 2 diabetes mellitus (DM2) and obesity.
Materials and methods.
The study included 32 patients treated by a combination of metformin (500-2550 mg/day) and sitagliptin (100 mg) for18 weeks. Standard parameters of carbohydrate and lipid metabolism, body mass index (BMI), blood adiponectin and leptin levels were measured, indices of insulin resistance and functional activity of pancreatic beta-cells were calculated.
Results.
Therapy with metformin-sitagliptin combination ensured compensation of fasting and postprandial hyperglycemia, reduced HbA1c level, increasedfunctional activity of beta-cells, decreased peripheral insulin resistance and BMI, had beneficial effect on lipid metabolism and hormonalactivity of adipose tissue.
Conclusion.
Metformin-sitagliptin combination can be recommended as a clinically efficacious modality for the treatment of patients with diabetesmellitus and obesity.
About the Authors
Alexander Sergeevich Ametov
ГОУ ДПО Российская медицинская академия последипломного образования, Москва
Elena Nikolaevna Pakus
ГОУ ДПО Российская медицинская академия последипломного образования, Москва
References
1. Аметов А.С., Солуянова Т.Н. Современные подходы к комбинированному лечению сахарного диабета 2 типа // Consilium medicum. - 2007. - Том 9, № 9. - С. 16-22.
2. Анциферов М.Б., Дорофеева Л.Г. Инкретиномиметики в терапии сахарного диабета 2 типа // Леч. врач. - 2009. - № 3. - С. 14-21.
3. Мкртумян А.М. Патофизиологический подход в лечении сахарного диабета 2 типа // Леч. врач. - 2008. - № 3. - С. 92-94.
4. Barnett A., Ausworth J., Jameson K., Mann R. A review of the effects of antihyperglycaemic agents on body weight: the po-tential of incretin targeted therapies // Curr. Med. Res. Opin. - 2007. - V. 23. - P. 1493-1507.
5. Farilla L., Bulotta A., Hirshberg B., Li C.S., Khoury N., Noush-mehr H., Bertolotto C., Di Mario U., Harlan D.M., Perfetti R. GLP-1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets // Endocrinology. - 2003. - V. 29. - P. 213-219.
6. Дедов И.И., Мельниченко Г.А. Ожирение: этиология, патогенез, клинические аспекты. Руководство для врачей. - М.: Медицинское ин- формационное агентство, 2004. - 456 с.
7. Балаболкин М.И., Дедов И.И., Гончаров Н.П., Клебанова Е.М., Мамаева Г.Г., Креминская В.М., Колесникова Г.С. Изменение содержа- ния лептина и растворимого рецептора к лептину в сыворотке крови у больных сахарным диабетом типа 2 при терапии формином // Ла- боратория. - 2004. - № 4. - C. 10-11.
8. Trujillo M.E., Scherer P.E. Adiponectin: journey from an adipo-cyte secretory protein to biomarker of the metabolic syn-drome // J. Intern. Med. - 2005. - V. 257. - P. 167-175.
Review
For citations:
Ametov A.S., Pakus E.N. Efficacy and safety of metformin-sitagliptin combination for the treatment of patients with diabetes mellitus and obesity. Diabetes mellitus. 2010;13(3):62-65. (In Russ.) https://doi.org/10.14341/2072-0351-5490
Views:
2699
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
